Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4456590
Max Phase: Preclinical
Molecular Formula: C19H20N6O7S
Molecular Weight: 476.47
Molecule Type: Unknown
Associated Items:
ID: ALA4456590
Max Phase: Preclinical
Molecular Formula: C19H20N6O7S
Molecular Weight: 476.47
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CN(Cc1cc2c(=O)[nH]c(N)nc2[nH]1)C(=O)c1csc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)c1
Standard InChI: InChI=1S/C19H20N6O7S/c1-25(6-9-5-10-14(21-9)23-19(20)24-15(10)28)17(30)8-4-12(33-7-8)16(29)22-11(18(31)32)2-3-13(26)27/h4-5,7,11H,2-3,6H2,1H3,(H,22,29)(H,26,27)(H,31,32)(H4,20,21,23,24,28)/t11-/m0/s1
Standard InChI Key: QOIFCZFQKZPNJR-NSHDSACASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 476.47 | Molecular Weight (Monoisotopic): 476.1114 | AlogP: 0.21 | #Rotatable Bonds: 9 |
Polar Surface Area: 211.57 | Molecular Species: ACID | HBA: 8 | HBD: 6 |
#RO5 Violations: 1 | HBA (Lipinski): 13 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.14 | CX Basic pKa: 4.60 | CX LogP: -1.81 | CX LogD: -7.19 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.25 | Np Likeness Score: -0.69 |
1. Xiang W, Dekhne A, Doshi A, O'Connor C, Hou Z, Matherly LH, Gangjee A.. (2019) Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis., 27 (23): [PMID:31679978] [10.1016/j.bmc.2019.115125] |
Source(1):